Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
1(25.0%)
Early Phase 1
1(25.0%)
4Total
N/A(2)
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05647278Phase 4Completed

Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)

Role: lead

NCT06196658Early Phase 1Not Yet Recruiting

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Role: lead

NCT05903703Not ApplicableNot Yet Recruiting

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Role: lead

NCT05648318Not ApplicableCompleted

Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients

Role: lead

All 4 trials loaded